• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- Studies show how common long COVID is globally and in teens

Lance

MPH, CSP & CIT Retired, CHMM Emeritus
https://www.cidrap.umn.edu/covid-19/studies-show-how-common-long-covid-globally-and-teens

Studies show how common long COVID is globally and in teens



Stephanie Soucheray, MA


23 minutes ago.

COVID-19
Long COVID, the post-infection condition that can encompass a number of symptoms in the weeks following an active COVID-19 infection, is shown to be highly prevalent in a new global analysis of studies published in Open Forum Infectious Diseases.

A second study in The Journal of Infectious Diseases describes the prevalence of long COVID in adolescents in the summer of 2022, and shows that while many teens report lingering symptoms, most are resolved by 3 months post-infection.

In the first study, analysis of 144 studies showed the global pooled long-COVID prevalence through May 2024 was 36% (95% confidence interval [CI], 33% to 40%). Long COVID was persistent when study follow-up was 1 or 2 years, but overall prevalence estimates varied widely across studies, ranging from 3% to 80% in studies published last year.

Among studies from North America, the estimated pooled prevalence was 30% (95% CI, 24% to 38%).

Factors associated with long COVID


In analyzing risk factors, the three strongest for long COVID were being unvaccinated (odds ratio [OR], 2.09; 95% CI, 1.55 to 2.81, meta-analyzed from 7 studies), infections from pre-Omicron variants (OR, 1.74; 95% CI, 1.40 to 2.17, from 6 studies), and female sex (OR, 1.56; 95% CI, 1.32 to 1.84, from 33 studies).

Studies that included only hospitalized patients found higher rates of long COVID than those who had patients with mild cases of the virus.

The two most commonly identified long-COVID symptoms were memory problems and muscle weakness, both with estimated prevalence of 11%.

"We caution that our pooled prevalence estimates represent the percentage of individuals who ever experienced long COVID symptoms during study follow-up, rather than those who are currently experiencing symptoms at a specific point in time, among those with a history of COVID infection," the authors said. "Therefore, our pooled estimates may overstate the clinical burden of long COVID."

Lower prevalence in teens at 3 months


US teens surveyed about long COVID in the summer of 2022 describe symptoms at 4 weeks post-infection that improved by 3 months post-infection, according to the second study.

Surveys were given to 784 respondents ages 12 to 17. Of those participants, 264 (34%) said they had tested positive for COVID-19, 291 (37%) never tested positive, and 229 (29%) were never tested for SARS-CoV-2 infection.

At least one symptom lasting 4 weeks or longer were reported by 41% of the positive respondents, compared to 12% of negative respondents and 11% of never-tested respondents. There was no association between COVID variant and odds of reporting lasting symptoms.

"Most symptoms resolved within three months, and less than 30% of adolescents reporting symptoms who tested positive reported their symptoms persisted for three or more months," the authors concluded.
 
Back
Top Bottom